


COMPANY OVERVIEW

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variation, and biological function.

Illumina is a publicly held company valued at \$28 billion.

By 2013, Illumina’s technology had reduced the cost of human genome sequencing from US \$1 million (2007) to US \$4,000.



Patinformatics, LLC®
Patent Landscape Reports

ANALYSIS:






The majority of the Illumina patent portfolio covers the chemistry associated with their testing machines. The patent portfolio in this area has grown significantly in the past few years.

Looking more specifically, patenting in the area of genetic sequence related measurements are responsible for the majority of the recent growth. The company also has patents on the apparatuses they build to do the measurements.

Only one of the top inventors remains with the company currently.

About 70% of the portfolio was generated organically. The remainder was primarily acquired through the purchase of Advanced Liquid Logic.

Illumina tends to cite their own patents frequently, but Pacific Bioscience, Complete Genomics, Thermo Fisher, and Bio-Rad have also shown interest in the Illumina portfolio based on forward citations.



Patinformatics, LLC®
Patent Landscape Reports